Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: a retrospective analysis
- 15 July 2004
- journal article
- research article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 59 (4) , 1148-1156
- https://doi.org/10.1016/j.ijrobp.2003.12.013
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Amifostine (Ethyol®): Dosing, administration and patient management guidelinesEuropean Journal Of Cancer, 1996
- The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol®)European Journal Of Cancer, 1996
- Use of radiation with or without WR-2721 in advanced rectal cancerCancer, 1992
- Topical or Systemic 16,16 Dm Prostaglandin E2or WR-2721 (WR-1065) Protects Mice from Alopecia after Fractionated IrradiationInternational Journal of Radiation Biology, 1992
- Pharmacokinetics of WR-2721Pharmacology & Therapeutics, 1988
- Radioprotectors in tumor radiotherapy: factors and settings determining therapeutic ratioPharmacology & Therapeutics, 1988
- Clinical trials of WR-2721 with radiation therapyInternational Journal of Radiation Oncology*Biology*Physics, 1982